ONCODESIGN: COVID-19 did not undermine Oncodesign’s mid-term prospects | CORPORATE | EUR15 (+8%)
ONCODESIGN - CORPORATE | EUR15 (+8%)COVID-19 did not undermine Oncodesign’s mid-term prospects
Challenging year due to COVID but 2021 may hold good surprises
A solid H2 and a promising 2021 based on a strong order book
Significant upsides to our scenario should come from the Pharma BU
We maintain our EUR15 TP
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.